Sennidine B

CAS: 517-44-2

Ref. 3D-FS137907

Product Information

• Name: Sennidine B
• Synonyms: (9,9'-Bianthracene)-2,2'-dicarboxylic acid, 9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo-, (R*,S*)-, 4,4',5,5'-Tetrahydroxy-10,10'-Dioxo-9,9',10,10'-Tetrahydro-9,9'-Bianthracene-2,2'-Dicarboxylic Acid, 9-[(9R)-2-carboxy-4,5-dihydroxy-10-oxo-9H-anthracen-9-yl]-4,5-dihydroxy-10-oxo-9H-anthracene-2-carboxylic acid, Nsc 658576, Sennidin B, [9,9′-Bianthracene]-2,2′-dicarboxylic acid, 9,9′,10,10′-tetrahydro-4,4′,5,5′-tetrahydroxy-10,10′-dioxo-, (9R,9′S)-rel-, [9,9′-Bianthracene]-2,2′-dicarboxylic acid, 9,9′,10,10′-tetrahydro-4,4′,5,5′-tetrahydroxy-10,10′-dioxo-, (R*,S*)-, [9,9′-Bianthracene]-2,2′-dicarboxylic acid, 9,9′,10,10′-tetrahydro-4,4′,5,5′-tetrahydroxy-10,10′-dioxo-, meso-, rel-(9R,9′S)-9,9′,10,10′-Tetrahydro-4,4′,5,5′-tetrahydroxy-10,10′-dioxo[9,9′-bianthracene]-2,2′-dicarboxylic acid

Description

Sennidine B is a chemical compound that has been shown to have anti-inflammatory, analgesic, and antipyretic effects. It is a prodrug that undergoes deacetylation in the liver to form Sennidine A, which is then metabolized by hydrolysis to produce the active form of the drug. The plasma concentration-time curve of Sennidine B was found to be biphasic with an initial phase characterized by rapid absorption and a terminal phase characterized by slower absorption. In histochemical staining studies, it was found that Sennidine B binds to proteins in human feces and can be detected using diagnostic methods such as immunohistochemistry or Western blotting. Sennidine B has also been shown to have probiotic properties, promoting the growth of beneficial bacteria such as Lactobacillus acidophilus in human intestines.
Sennidine B has been shown to inhibit fatty acid uptake into cells and promote fat metabolism through its ability to

• Brand: Biosynth

Chemical properties

• Molecular weight: 538.46 g/mol
• Purity: Min. 95%